Key Takeaways:
- 1. Paradromics, a U.S. neurotechnology startup, has gained FDA approval for a human trial to test their fully implantable device for restoring speech in people with paralysis.
- 2. The Paradromics device, called Connexus BCI, captures neural signals to enable real-time communication for those who cannot speak.
- 3. The trial will evaluate the safety and efficacy of the device in converting neural activity into text or a synthetic voice, potentially benefiting individuals with conditions like ALS or stroke.
Paradromics is at the forefront of brain-computer interface technology with their fully implantable Connexus BCI device, approved for a trial focused on speech restoration. The device uses high-resolution electrodes to capture neural signals for communication. If successful, this breakthrough could revolutionize assistive communication for those with speech impairments, offering real-time speech generation and hands-free computer control.
Insight: The Paradromics trial represents a significant step in advancing neurotechnology for restoring communication abilities in individuals with paralysis, potentially offering new possibilities for independence and daily living improvements.
This article was curated by memoment.jp from the feed source: Fox Scitech.
Read the full article here: https://www.foxnews.com/tech/fully-implantable-brain-chip-aims-restore-real-speech
© All rights belong to the original publisher.
